Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer

Oncogene volume 26, pages 3654–3660 (2007)Cite this article

Abstract

The recent successful development of monoclonal antibodies that target key components of biological pathways has expanded the armamentarium of treatment options for patients with colorectal cancer (CRC). In particular, the epidermal growth factor receptor (EGFR), a tyrosine kinase growth factor receptor involved in CRC development and progression, is exploited by the newest monoclonal antibody that is available for use in CRC patients. Cetuximab, the first chimeric monoclonal antibody, which has been generated against the EGFR, is currently registered in USA, Europe and worldwide, in combination with irinotecan in the treatment of metastatic CRC patients who have progressed on irinotecan containing chemotherapy. Cetuximab is well tolerated and does not exacerbate the toxicity of concomitant chemotherapy. Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naïve patients with metastatic CRC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Abubakr Y, Eng C, Pautret V, Maurel J, Scheithauer W, Kroening H et al. (2006). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol. ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): 3556.

  • Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L . (1999). Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884–2890.

    CAS  PubMed  Google Scholar 

  • Arteaga CL . (2001). The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32–40.

    Google Scholar 

  • Badarinath SME, Jennis A . (2004). Cetuximab plus FOLFOX for colorectal (EXPLORE): preliminary safety analysis of a randomized phase III trial. Presented at the 2004 American Society of Clinical Oncology Annual Meeting New Orleans, Louisiana.

  • Barber TD, Vogelstein B, Kingzler KW, Velculescu VE . (2004). Somatic mutations of EGFR in colorectal cancer and glioblastomas. New Engl J Med 351: 2883.

    Article  CAS  Google Scholar 

  • Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M et al. (2000). Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904–914.

    Article  CAS  Google Scholar 

  • Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P et al. (2000). Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343–4350.

    CAS  PubMed  Google Scholar 

  • Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P . (2004). New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100: 1558–1577.

    Article  CAS  Google Scholar 

  • Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ et al. (2000). Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6: 1936–1948.

    CAS  PubMed  Google Scholar 

  • Busam KJ, Capodieci P, Motzer R Kiehn T, Phelan D, Halpern AC . (2001). Cutaneous side effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144: 1169–1176.

    Article  CAS  Google Scholar 

  • Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S et al. (1999). Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909–916.

    CAS  PubMed  Google Scholar 

  • Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G et al. (2000). Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739–3747.

    CAS  PubMed  Google Scholar 

  • Ciardiello F, Tortora G . (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958–2970.

    CAS  PubMed  Google Scholar 

  • Ciardiello F, Tortora G . (2002). Anti-epidermal growth receptor drugs in cancer therapy. Expert Opin Investig Drugs 11: 755–768.

    Article  CAS  Google Scholar 

  • Cohen RB, Falcey JW, Paulter WJ, Fetzer KM, Waksal HW . (2000). Safety profile of the monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR- positive tumors. Proc Am Soc Clin Oncol 19: Abs 1862.

  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004). A randomized comparison of cetuximab monotherapy and cetuximab plus irinotecan in irino-tecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.

    Article  CAS  Google Scholar 

  • Debaldo C, Pierga JY, Dieras V . (2003). Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of phase I study. Eur J Cancer, (Suppl 1);Abstract 552.

  • Folprecht G, Lutz MP, Schoeffski P, Seufferlein C, Nolting A, Pollert P et al. (2005). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450–456.

    Article  Google Scholar 

  • Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M et al. (2006). Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13: 823–835.

    Article  Google Scholar 

  • Grunwald V, Hidalgo M . (2003). Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851–867.

    Article  Google Scholar 

  • Herbst RS, Shin DM . (2002). Monoclonal antibodies to target epidermal growth factor receptor positive tumours: a new paradigm for cancer therapy. Cancer 94: 1593–1611.

    Article  CAS  Google Scholar 

  • Hohler T . (2004). Phase I/II study of cetuximab combined with 5-fluorouracil/ leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer. Presented at the European Society of Medical Oncology Congress, Vienna, Austria 29–November 2.

  • Holliwood E . (2002). Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Semin Oncol Nurs 18: 30–35.

    Article  Google Scholar 

  • Huang SM, Bock JM, Harari PM . (1999). Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 15: 1935–1940.

    Google Scholar 

  • Huang SM, Harari P . (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166–2174.

    CAS  PubMed  Google Scholar 

  • Humblet Y . (2004). Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor expressing tumours. Expert Opin Pharmacother 5: 1621–1633.

    Article  CAS  Google Scholar 

  • Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ et al. (2000). Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874–4884.

    CAS  PubMed  Google Scholar 

  • Kim ES, Khuri FR, Herbst RS . (2001). Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13: 506–513.

    Article  CAS  Google Scholar 

  • Lee E, Hoff PM . (2004). Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol 22: 1177–1179.

    Article  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan W et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.

    Article  CAS  Google Scholar 

  • McClelland RA, Barrow D, Madden TA Butkowski CM, Pamment J, Knowlden JM et al. (2001). Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776–2788.

    Article  CAS  Google Scholar 

  • Mendelsohn J . (2000). Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 6: 747–753.

    CAS  PubMed  Google Scholar 

  • Mendelsohn J . (2001). The epidermal growth factor receptor as a target for cancer therapy. Endocrine Related Cancer 8: 3–9.

    Article  CAS  Google Scholar 

  • Mendelsohn J, Baselga J . (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787–2799.

    Article  CAS  Google Scholar 

  • Milas L, Mason K, Hunter N, Peterson S, Yamakawa M, Ang K ;et al. (2000). In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701–708.

    CAS  PubMed  Google Scholar 

  • Olayioye MA, Neve RM, Lane HA, Hynes NE . (2001). The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159–3167.

    Article  Google Scholar 

  • Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J . (1996). Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56: 3666–3669.

    CAS  PubMed  Google Scholar 

  • Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ et al. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257–265.

    CAS  PubMed  Google Scholar 

  • Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ . (2002). Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal cancer xenografts. Clin Cancer Res 8: 994–1003.

    CAS  PubMed  Google Scholar 

  • Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB et al. (2001). Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234–3243.

    Article  CAS  Google Scholar 

  • Rosemberg AH, Loeherer PJ, Needle MN, Waksal H, Hollywood E, Ramos L et al. (2002). Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that express the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol Abs 536.

  • Saleh MH, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS et al. (1999). Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14: 451–463.

    Article  CAS  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F, Normanno N . (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 19: 183–232.

    Article  CAS  Google Scholar 

  • Salomon DS, Gullick W . (2001). The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2: 4–11.

    Google Scholar 

  • Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. . (2003). The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22: Abs 817.

  • Saltz L, Lenz H, Kindler H, Hochster H, Wadler S, Hoff P et al. (2005). Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/irinotecan (CB) in irinotecan-refractory colorectal cancer. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium, Hollywood, FL, January 27–29.

  • Saltz L, Meropol NJ, Loeher PJ, Needle MN, Kopit J, Mayer RJ . (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208.

    Article  CAS  Google Scholar 

  • Saltz L, Rubin M, Hochster H, Hochster H, Wadler S, Hoff P et al. (2001). Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20: Abst 7.

  • Wosikowski K, Schuuruis D, Kops GJPL, Saceda M, Bates SE . (1997). Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 3: 2405–2414.

    CAS  PubMed  Google Scholar 

  • Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A et al. (1996). Involvement of p27kip1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12: 1397–1403.

    CAS  PubMed  Google Scholar 

  • Yarden Y, Sliwkowski MX . (2001). Untantling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgery, ‘F Magrassi–A Lanzara’ Department of Clinical and Experimental Medicine and Surgery, PhD Degree Program in Medical and Surgical Oncology and Clinical Immunology, Second University of Naples School of Medicine, Naples, Italy

    G Galizia, E Lieto, P Castellano & V Imperatore

  2. Division of Medical Oncology, ‘F Magrassi - A Lanzara’ Department of Clinical and Experimental Medicine and Surgery, PhD Degree Program in Medical and Surgical Oncology and Clinical Immunology, Second University of Naples School of Medicine, Naples, Italy

    F De Vita, M Orditura, T Troiani & F Ciardiello

Authors
  1. G Galizia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Lieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F De Vita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Orditura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Castellano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Troiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Imperatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Ciardiello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Galizia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galizia, G., Lieto, E., De Vita, F. et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26, 3654–3660 (2007). https://doi.org/10.1038/sj.onc.1210381

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210381

Keywords

This article is cited by

Search

Advanced search

Quick links